Evotec AG (FRA: EVT) has recently entered into a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets as potential points of intervention in the treatment of Alzheimer's disease (AD).
The Research Institute of Molecular Pathology in Vienna (IMP) is also involved in the said collaboration.
Evotec scientists together with the IMP will apply their proprietary and well validated disease models to identify novel AD targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery programme with the goal of developing innovative novel therapeutics.
The financial details of the transaction were not disclosed.
Source: Evotec AG
.jpg)
Comment Preview